Highlights Heidelberg Pharma AG

Equities

HPHA

DE000A11QVV0

Real-time Estimate Tradegate Other stock markets 05:30:00 2024-07-16 am EDT			5-day change	1st Jan Change
2.585 ^EUR	-0.58%		+1.15%	-29.68%

Jul. 11	Heidelberg Pharma AG Reports Earnings Results for the Half Year Ended May 31, 2024	CI
Apr. 25	Heidelberg Pharma AG Reports Earnings Results for the First Quarter Ended February 29, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Heidelberg Pharma AG Reports Earnings Results for the Half Year Ended May 31, 2024	Jul. 10	CI
Heidelberg Pharma AG Reports Earnings Results for the First Quarter Ended February 29, 2024	Apr. 24	CI
Heidelberg Pharma AG Reports Earnings Results for the Full Year Ended November 30, 2023	Mar. 24	CI
Heidelberg Pharma Concludes Royalty Purchase Deal with HealthCare Royalty	Mar. 19	MT
Heidelberg Pharma Unit Secures European Patent for Amanitin Toxin-Based Antibody-Drug Conjugates	Nov. 15	MT
Heidelberg Pharma AG Reports Earnings Results for the Nine Months Ended August 31, 2023	23-10-12	CI
Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with Lead Candidate HDP-101	23-09-19	CI
Heidelberg Pharma AG Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2023	23-07-13	CI
Heidelberg Pharma AG Reports Earnings Results for the First Quarter Ended February 28, 2023	23-04-12	CI
Heidelberg Pharma AG Provides Earnings Guidance for the Year 2023	23-03-27	CI
Heidelberg Pharma AG Reports Earnings Results for the Full Year Ended November 30, 2022	23-03-23	CI
Heidelberg Pharma AG Reports Earnings Results for the Full Year Ended November 30, 2022	23-03-23	CI
Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform	22-12-16	CI
Heidelberg Pharma Ag Announces Encouraging Clinical Data from Two Antibody Drug Conjugates Based on Heidelberg Pharma’s ATAC Technology	22-12-13	CI
Heidelberg Pharma AG Reports Earnings Results for the Nine Months Ended August 31, 2022	22-10-13	CI
Heidelberg Pharma Unit Signs License Deal With Japan's Takeda For Antibody Targeted Amanitin Conjugate	22-09-12	MT
Chiome Bioscience Signs Research and Option Agreement with Heidelberg Pharma	22-07-14	MT
Heidelberg Pharma Enters Research Collaboration Deal With Japan's Chiome Bioscience	22-07-13	MT
Chiome Bioscience Inc. Announces Conclusion of Target-Specific Research and Option Agreement with Heidelberg Pharma	22-07-13	CI
Heidelberg Pharma AG Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2022	22-07-12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Heidelberg Pharma AG

Equities

HPHA

DE000A11QVV0

Highlights

Filters